Skip to content
10-K

Annual Report

CNS Pharmaceuticals, Inc. CNSP

0001683168-25-002139

← back to feed
Filed
Mar 31, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted restated FY 2024 · Dec 31, 2023 1.51K sh
Capex FY 2024 · Dec 31, 2023 $3.9K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$14.14M
Cash And Equivalents FY 2024 · Dec 31, 2023 $548.72K
Current Liabilities FY 2024 · Dec 31, 2023 $6.13M
Total Liabilities FY 2024 · Dec 31, 2023 $6.13M
Current Assets FY 2024 · Dec 31, 2023 $1.59M
Total Assets FY 2024 · Dec 31, 2023 $1.7M
Eps Diluted restated FY 2024 · Dec 31, 2023 −$12,509.11
Eps Basic restated FY 2024 · Dec 31, 2023 −$12,509.11
Sga Expense FY 2024 · Dec 31, 2023 $4.77M
Rd Expense FY 2024 · Dec 31, 2023 $14.1M
Net Income FY 2024 · Dec 31, 2023 −$18.85M
Operating Income FY 2024 · Dec 31, 2023 −$18.87M
Stockholders Equity FY 2024 · Dec 31, 2022 $8.13M